NOVARTIS’ PAY-OUT APPEAL LESS IN DEMAND, FOR NOW (ADD; 8% UPSIDE)
21/12/20 -"2020 ridiculed various market notions, including the long-held principle of defensive investing in turbulent times. Hence, year-to-date, the Pharma sector lost 0.9% in value, which was not far away ..."
Pages
72
Language
English
Published on
21/12/20
You may also be interested by these reports :
14/09/26
Since its July 2022 listing, Haleon (BUY; UK) has delivered a total return of just under 20%. Unexciting, but not for want of progress. Assembled ...
11/09/26
The recent R&D setbacks in cardiovascular and neuroscience areas have prompted us to revise our target price downwards. In the process, we have also ...
10/09/26
After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of ...
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...